Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn

Protein Science

Volumn 18, Issue 2, 2009, Pages 424-433

  Pan, Hai ^a   Chen, Kenneth ^a   Chu, Liping ^a   Kinderman, Francis ^a   Apostol, Izydor ^a   Huang, Gang ^a  

^a AMGEN INC   (United States)

Author keywords

FcRn binding; Human IgG2 antibody; Methionine oxidation; Protein a binding; Protein a chromatography

Indexed keywords

IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G2; METHIONINE; PROTEIN A;

ARTICLE; BINDING AFFINITY; BINDING SITE; CHROMATOGRAPHY; CRYSTAL STRUCTURE; DISSOCIATION; OXIDATION; PH; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STABILITY; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY AFFINITY; CHO CELLS; CRICETINAE; CRICETULUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HYDROGEN-ION CONCENTRATION; IMMOBILIZED PROTEINS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; KINETICS; METHIONINE; MOLECULAR SEQUENCE DATA; OXIDATION-REDUCTION; PROTEIN BINDING; RECEPTORS, FC; SEQUENCE ALIGNMENT; STAPHYLOCOCCAL PROTEIN A; TERT-BUTYLHYDROPEROXIDE;

EID: 59949104434     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.45     Document Type: Article

References (54)

1. Shacter E (2000) Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 32: 307-326.
2. Scislowski PW, Foster AR, Fuller MF (1994) Regulation of oxidative degradation of L-lysine in rat liver mitochondria. Biochem J 300(Pt 3) :887-891.
3. Hovorka S, Schoneich C (2001) Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition. J Pharm Sci 90:253-269.
4. Slavica A, Dib I, Nidetzky B (2005) Single-site oxidation, cysteine 108 to cysteine sulfinic acid, in D-amino acid ox- idase from Trigonopsis variabilis and its structural and functional consequences. Appl Environ Microbiol 71: 8061-8068.
5. Lu HS, Fausset PR, Narhi LO, Horan T, Shinagawa K, Shimamoto G, Boone TC (1999) Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: effect on stability and biological activity. Arch Bio- chem Biophys 362:1-11.
6. Stadtman ER, Moskovitz J, Berlett BS, Levine RL (2002) Cyclic oxidation and reduction of protein methionine residues is an important antioxidant mechanism. Mol Cell Biochem 234-235:3-9.
7. Frelinger AL, III, Zull JE (1986) The role of the methio- nine residues in the structure and function of parathyroid hormone. Arch Biochem Biophys 244:641-649.
8. Teh LC, Murphy LJ, Huq NL, Surus AS, Friesen HG, Lazarus L, Chapman GE (1987) Methionine oxidation in human growth hormone and human chorionic somato- mammotropin. Effects on receptor binding and biological activities. J Biol Chem 262:6472-6477.
9. Sasaoki K, Hiroshima T, Kusumoto S, Nishi K (1989) Oxidation of methionine residues of recombinant human interleukin 2 in aqueous solutions. Chem Pharm Bull (Tokyo) 37:2160-2164.
10. Lam XM, Yang JY, Cleland J L (1997) Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 86:1250-1255.
11. Gao J, Yin DH, Yao Y, Sun H, Qin Z, Schoneich C, Williams TD, Squier TC (1998) Loss of conformational stability in calmodulin upon methionine oxidation. Biophys J 74:1115-1134.
12. Liu JL, Lu KV, Eris T, Katta V, Westcott KR, Narhi LO, Lu HS (1998) In vitro methionine oxidation of recombi- nant human leptin. Pharm Res 15:632-640.
13. Uversky VN, Yamin G, Souillac PO, Goers J, Glaser CB, Fink AL (2002) Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett 517:239-244.
14. Wood M J, Becvar LA, Prieto JH, Melacini G, Komives EA (2003) NMR structures reveal how oxidation inactivates thrombomodulin. Biochemistry 42:11932-11942.
15. Chen B, Mayer M U, Squier TC (2005) Structural uncoupling between opposing domains of oxidized calmodulin underlies the enhanced binding affinity and inhibition of the plasma membrane Ca-ATPase. Biochemistry 44:4737-4747.
16. Chugha P, Sage H J, Oas T G (2006) Methionine oxidation of monomeric lambda repressor: the denatured state ensemble under nondenaturing conditions. Protein Sci 15:533-542.
17. Brot N, Weissbach H (1983) Biochemistry and physiological role of methionine sulfoxide residues in proteins. Arch Biochem Biophys 223:271-281.
18. Glaser CB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I, Chang RJ, Lin JH, Vilander L, Andrews WH, et al (1992) Oxidation of a specific methionine in throm- bomodulin by activated neutrophil products blocks cofac- tor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest 90:2565-2573.
19. Dow LK, Changela A, Hefner HE, Churchill ME (1997) Oxidation of a critical methionine modulates DNA binding of the Drosophila melanogaster high mobility group protein, HMG-D. FEBS Lett 414:514-520.
20. Kornfelt T, Persson E, Palm L (1999) Oxidation of methi- onine residues in coagulation factor VIIa. Arch Biochem Biophys 363:43-54.
21. Brekke OH, Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2:52-62.
22. Maggon K (2007) Monoclonal antibody "gold rush". Curr Med Chem 14:1978-1987.
23. Burton DR (1985) Immunoglobulin G: functional sites. Mol Immunol 22:161-206.
24. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev 6:343-357.
25. Sjodahl J (1977) Structural studies on the four repetitive Fc-binding regions in protein A from Staphylococcus aureus. Eur J Biochem 78:471-490.
26. Burmeister WP, Huber AH, Bjorkman PJ (1994) Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372:379-383.
27. Langone J J (1982) Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumonococci. Adv Immunol 32: 157-252.
28. Moks T, Abrahmsen L, Nilsson B, Hellman U, Sjoquist J, Uhlen M (1986) Staphylococcal protein A consists of five IgG-binding domains. Eur J Biochem 156:637-643.
29. Simister NE, Mostov KE (1989) An Fc receptor structurally related to MHC class I antigens. Nature 337:184-187.
30. Ghetie V, Ward ES (2000) Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 18:739-766.
31. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev 7:715-725.
32. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE (1996) Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 89:573-578.
33. Lobo ED, Hansen R J, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668.
34. Shen FJ, Kwong MY, Keck RG, Harris RJ (1996) The application of tert-butylhydroperoxide oxidation to study sites of potential methionine oxidation in a recombinant antibody. Tech Protein Chem 7:275-284.
35. Chumsae C, Gaza-Bulseco G, Sun J, Liu H (2007) Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. J Chromatogr 850:285-294.
36. Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, Li L, Brems DN, Remmele RL, Jr (2008) Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 47:5088-5100.
37. Vriend G, Krause R (2007) WHAT IF. Available at: http://swift.cmbi.kun. nl/WIWWWI/accessed March 2008.
38. Hober S, Nord K, Linhult M (2007) Protein A chroma- tography for antibody purification. J Chromatogr 848: 40-47.
39. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D (2007) Downstream processing of monoclonal antibodies-application of platform approaches. J Chromatogr 848:28-39.
40. Gaza-Bulseco G, Faldu S, Hurkmans K, Chumsae C, Liu H (2008) Effect of methionine oxidation of a recombi- nant monoclonal antibody on the binding affinity to protein A and protein G. J Chromatogr 870:55-62.
41. Deisenhofer J (1981) Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 20:2361-2370.
42. Kato K, Gouda H, Takaha W, Yoshino A, Matsunaga C, Arata Y (1993) 13C NMR study of the mode of interaction in solution of the B fragment of staphylococcal protein A and the Fc fragments of mouse immunoglobulin G. FEBS Lett 328:49-54.
43. Martin WL, Bjorkman PJ (1999) Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry 38:12639-12647.
44. West AP, Jr, Bjorkman PJ (2000) Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 39:9698-9708.
45. Martin WL, West AP, Jr, Gan L, Bjorkman PJ (2001) Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 7:867-877.
46. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276: 6591-6604.
47. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169:5171-5180.
48. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vasquez M, Tsur- ushita N (2004) Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 279: 6213-6216.
49. Vaccaro C, Zhou J, Ober RJ, Ward ES (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 23:1283-1288.
50. Dall'Acqua WF, Kiener PA, Wu H (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514-23524.
51. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N (2006) An engineered human IgG1 antibody with longer serum half-life. J Immunol 176:346-356.
52. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18:1759-1769.
53. Sauer-Eriksson AE, Kleywegt GJ, Uhlen M, Jones TA (1995) Crystal structure of the C2 fragment of streptococ- cal protein G in complex with the Fc domain of human IgG. Structure 3:265-278.
54. Corper AL, Sohi MK, Bonagura VR, Steinitz M, Jefferis R, Feinstein A, Beale D, Taussig MJ, Sutton BJ (1997) Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol 4:374- 381.